Partnering for Novel Drug Discovery and Development

GigaGen collaborates with leading academic and biopharmaceutical researchers interested in using mouse and human antibodies to advance drug discovery and development programs. Our main areas of collaboration are:

  • Antibody discovery

  • Massively polyclonal natural repertoire antibodies

  • Cancer repertoire analysis

Please contact us for more information.

Grifols is a world leader in sales of plasma-derived polyclonal antibody therapies, including intravenous immunoglobulin. GigaGen and Grifols have entered into a major >$50 million co-development contract. The co-development contract involves use of GigaGen technology to develop the world's first recombinant polyclonal antibody drugs.

Stanford logo

Located between San Francisco and San Jose in the heart of Silicon Valley, Stanford University is recognized as one of the world's leading research and teaching institutions. GigaGen is collaborating with Stanford on clinical immune monitoring and translational immunology research.

UCSF logo

The leading university exclusively focused on health, UC San Francisco is driven by the idea that when the best research, the best education and the best patient care converge, great breakthroughs are achieved. GigaGen is working with UCSF to research antibody based targets against significant disease.


The COI approach is based on Avalon Ventures’ proven portfolio strategy for launching disruptive drug discovery, technology platform and healthcare IT companies in new market areas and providing ongoing support as they grow and increase in value. GigaGen is collaborating with COI to discover new autoimmune therapies.